In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The companies plan to start a pivotal Phase 3 trial in the coming months
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Subscribe To Our Newsletter & Stay Updated
